DXCM Form 4: Malady Sells Shares Under 10b5-1 Plan; Holds 22,667 Shares

Rhea-AI Filing Summary

Kyle Malady, a director of DexCom, Inc. (DXCM), reported a sale of common stock executed on 09/05/2025 under a previously adopted 10b5-1 trading plan. The Form 4 shows 667 shares were sold at $80.86 per share pursuant to the 10b5-1 plan adopted on 06/06/2025 to allow orderly dispositions. After the reported sale, Mr. Malady beneficially owned 22,667 shares, which include 5,192 unvested restricted stock units granted on 05/08/2025 that vest on the earlier of the one-year anniversary of the grant or DexCom’s 2026 Annual Meeting of Stockholders.

Positive

• Transaction conducted under a 10b5-1 plan, which the filer states "allows the orderly disposition of shares"
• Continued beneficial ownership of 22,667 shares after the sale, indicating ongoing equity stake
• Disclosure includes vesting terms for 5,192 restricted stock units granted 05/08/2025

Negative

• Disposition of 667 shares at $80.86 reduced the reporting person’s direct holdings
• 5,192 RSUs are unvested, indicating a portion of reported ownership is not currently transferable

Insights

Corporate Governance Expert

TL;DR Director sold a small number of shares under a pre-established 10b5-1 plan; remaining holdings include recently granted unvested RSUs.

The disclosure is a routine Section 16 transaction: Mr. Malady adopted a 10b5-1 plan on 06/06/2025 and executed a sale of 667 shares at $80.86 on 09/05/2025. The report shows continued beneficial ownership of 22,667 shares, including 5,192 unvested restricted stock units granted 05/08/2025 with a defined vesting condition tied to time or the 2026 annual meeting. For governance review, the filing documents adherence to an established trading plan and reports the nature and timing of equity grants and dispositions without other governance irregularities disclosed.

Securities Analyst

TL;DR Insider sale under a 10b5-1 plan, modest in size, with material detail on outstanding and unvested awards.

The Form 4 reports a disposition of 667 shares at $80.86 under a 10b5-1 plan adopted 06/06/2025. Post-transaction beneficial ownership is 22,667 shares, which explicitly includes 5,192 unvested RSUs granted 05/08/2025 that vest by time or the 2026 annual meeting. The filing provides clear transactional detail and award vesting terms useful for modeling insider liquidity and outstanding share counts, but it contains no earnings or operational data to affect financial forecasts directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Malady Kyle

(Last) (First) (Middle)

6340 SEQUENCE DRIVE

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
DEXCOM INC [ DXCM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/05/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/05/2025		S		667(1)	D	$80.86	22,667(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On June 6, 2025, Mr. Malady adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Malady. The shares set forth above were sold pursuant to the 10b5-1 Plan.

2. Included in this number are 5,192 unvested restricted stock units which were granted on May 8, 2025 and shall vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2026 Annual Meeting of Stockholders.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Jereme M. Sylvain, as Attorney-in-Fact for Kyle Malady	09/09/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What shares did Kyle Malady sell in the Form 4 for DXCM?

The Form 4 reports a sale of 667 shares of DexCom common stock executed on 09/05/2025 at a price of $80.86 per share.

Was the sale by Kyle Malady part of a 10b5-1 plan?

Yes. The sale was executed pursuant to a 10b5-1 trading plan adopted on 06/06/2025, which the filing states allows orderly disposition of shares.

How many shares does Kyle Malady beneficially own after the reported transaction?

Following the reported sale, Mr. Malady beneficially owned 22,667 shares in total.

Does the Form 4 disclose any unvested awards for Kyle Malady?

Yes. The filing states that included in the 22,667 shares are 5,192 unvested restricted stock units granted on 05/08/2025 that vest by the earlier of one year from grant or DexCom’s 2026 Annual Meeting.

At what price were the shares sold?

The disclosed sale price was $80.86 per share.